Privia Health price target lowered to $26 from $37 at Canaccord

Canaccord lowered the firm’s price target on Privia Health to $26 from $37 and keeps a Buy rating on the shares. The firm said Privia’s track record since coming public has been consistent, typically reporting better thanexpected results and maintaining annual guidance ranges, and often with favorable commentary toward the high-end. Encouragingly, Privia’s quarterly reports lack drama which reinforces the strength of a business model.